How many investments has Polaris Partners made?

Polaris Partners has 130 tracked investments, 35 of which have exited, including 16 dated in the last 24 months.

What stage does Polaris Partners invest at?

Polaris Partners invests at the Seed, Series A, Series B, Series C, Growth stages.

What is Polaris Partners's typical check size?

Polaris Partners typically writes checks of $500K – $5M.

What sectors does Polaris Partners focus on?

Polaris Partners focuses on Biotech, Consumer, Digital Health, Healthtech.

Where is Polaris Partners located?

Polaris Partners is headquartered in Boston, US.

Polaris Partners

Venture capitalActively deployingoperating company · company profile

Boston · Seed–Growth · 45 people tracked

Also known as Polaris Growth Fund · POLARIS GROWTH MANAGEMENT, LLC

Not to be confused with Polaris Partners (Venture capital · Boston, US)

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Polaris Partners

Paths you didn't know you had: your email and LinkedIn already hold routes to the Polaris Partners team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict

Investment thesis

Polaris Partners emphasizes real partnership as the foundation for building great companies. For nearly three decades, the firm has collaborated with talented biotech and healthcare entrepreneurs, backing transformational companies in these fields. Its approach centers on doing well by working together with founders throughout the company-building journey.

Invests inBiotech Consumer Digital Health Healthtech Asia-Pacific Boston Europe United States

Source: firm website, verified Sep 29, 2026.

Leave your own feedback

Stage

Seed–Growth

Check

$500K – $5M

Boston, Massachusetts, US

Instruments

Equity

Founded

1995

Last 12 months

9 investments

AUM

$4.2B

Tracked investments

130

Unicorns

IPOs

Acquisitions

Team · 45 people

from the firm's website & curated & public directories

Jon Flint· Founding Partner· Massachusettsin 𝕏

Jon Flint co-founded Polaris Partners with Steve Arnold and Terry McGuire in 1996. He began his venture career in 1984 at Burr, Egan, Deleage & Co., where he became a General Partner and helped build the firm's technology portfolio, having previously worked as a litigation associate at the Boston law firm Testa, Hurwitz and Thibeault and served on research teams for the Nixon Impeachment Inquiry Staff and the Watergate Special Prosecution Force. In 2005 he conceived of and co-founded Living Proof, and in 2015 he and Terry McGuire formed Polaris Founders Capital to invest their own capital across stages and sectors.

jf@polarispartners.com

Terry McGuire· Founding Partner· Massachusettsin

tm@polarispartners.com

Eileen McGuire· General Partner· Boston, Massachusetts, United Statesin

Terrance G. McGuire· General Partner

Alan Crane· Entrepreneur Partnerin

Alan Crane joined Polaris Partners in 2002 as an entrepreneur partner, focusing on building and investing in healthcare companies. He has held founder, CEO, and Chairman roles across ten Polaris companies, including co-founding Zag Bio, Seismic Therapeutic, and Dyno Therapeutics, and founding Pandion Therapeutics (acquired by Merck). He was previously president and CEO of Momenta Pharmaceuticals (acquired by J&J) and SVP of corporate development at Millennium Pharmaceuticals, and holds degrees from Harvard College, Harvard Graduate School of Arts & Sciences, and Harvard Business School.

acrane@polarispartners.com

Alexandra Cantley· Managing Partner· New York, New Yorkin 𝕏

Alexandra Cantley is a managing partner at Polaris Partners, which she joined in 2019, working from the New York office with a focus on early-stage biotech and healthcare investments. Before Polaris, she was part of the initial research team at Inzen Therapeutics and previously held a research fellowship at Vertex Pharmaceuticals. She holds a PhD in Chemical Biology from Harvard University and completed her undergraduate studies at New York University.

Amir Nashat· Entrepreneur Partner· Bostonin 𝕏

Amir Nashat is an entrepreneur partner at Polaris Partners in Boston, where he invests in healthcare companies and takes on executive roles inside portfolio companies. He joined the firm in 2002 and serves as a managing partner of Polaris Funds VI through IX. He has repeatedly stepped in as CEO of Polaris-backed startups, including Dewpoint Therapeutics, Jnana, Living Proof, Olivo Labs, Paratus Sciences, and Sun Catalytix, and is currently CEO of Souffle Therapeutics. He earned a doctorate in chemical engineering at MIT under Robert Langer and holds materials science and mechanical engineering degrees from UC Berkeley, and was named to the Forbes Midas List in 2016.

anashat@polarispartners.com

Amy Schulman· Managing Partner· Mount Pleasant, South Carolina

Amy Schulman is a managing partner at Polaris Partners focused on healthcare companies and early stage biotech startups. She joined the firm in 2014 and co-founded the Polaris Innovation Fund in 2017, which she continues to manage. Before Polaris she held roles at Pfizer including general counsel and president of Pfizer Nutrition and Pfizer Consumer Healthcare, was a partner at DLA Piper, and began her career at Cleary Gottlieb Steen & Hamilton; she is also a Senior Lecturer at Harvard Business School and holds degrees from Wesleyan University and Yale Law School.

aschulman@polarispartners.com

Brian Chee· Managing Partner· San Francisco, Californiain 𝕏

Brian Chee is a managing partner at Polaris Partners in San Francisco who invests in healthcare companies. He joined Polaris as an associate in Boston shortly after the firm's founding in 1996, and previously worked at Goldman Sachs in New York and San Francisco and at Baxter Healthcare, where he developed experience across medical devices, pharmaceuticals, and biotechnology. He holds a BS from the United States Military Academy at West Point and an MBA from the Tuck School of Business at Dartmouth College, and served as a Captain in the US Army Corps of Engineers.

bchee@polarispartners.com

Chen-Ee Lee· Partner

Ellie McGuire· Managing Partner· Boston, Massachusettsin

Ellie McGuire is a managing partner in Polaris Partners' Boston office and manages the Polaris Innovation Fund, which she co-founded. Before Polaris, she was head of business development at Lyndra and held leadership and consulting roles in business development, operations, and strategy at life science companies including Arsia Therapeutics, SQZ Biotechnologies, and XTuit Pharmaceuticals. She also serves as an expert in residence for the Harvard Office of Technology Development.

emcguire@polarispartners.com

Gary Swart· Operating Partner· Athertonin 𝕏

Gary Swart is an operating partner at Polaris Partners in San Francisco, where he invests in healthcare services and products. He previously served as CEO of oDesk (later Upwork), which merged with Elance, and earlier held roles as Chief Revenue Officer of Intellibank and a business unit executive at IBM following its acquisition of Rational Software. He also mentors at accelerators including Alchemist and StartX.

gswart@polarispartners.com

Jonathan Ang· Entrepreneur Partner· Singaporein

Jonathan Ang joined Polaris Partners in 2023 as an entrepreneur partner in the firm's Singapore office, where he focuses on investing in, building, and scaling healthcare companies. Previously he was a Director on the Life Sciences Team at Temasek International in Singapore, managing its global healthcare services investment strategy and co-leading investments across multiple regions. He began his career on Cowen's Health Care Banking Team in New York and London, and holds an honors degree in Economics from The Wharton School of the University of Pennsylvania.

Bryce David Youngren· Managing Partner· Waltham, Massachusettsin 𝕏

Dan Lombard· Managing Partner· Boston, Massachusettsin

Darren Carroll· Partner· Boston, Massachusettsin

Sabrina Chiasson· Partner· Boston, Massachusettsin

Brian Lewis· Director, Legal & Investment Analytics· San Franciscoin

Brian Lewis joined Polaris in 2019 as director of legal and investment analytics in the firm's San Francisco office, where he handles investment analytics projects along with legal operations and deal matters. He previously worked at Latham & Watkins LLP, first as a senior paralegal and then as a quantitative analysis manager in the corporate department, supporting financial and capitalization modeling for equity financings, acquisitions, and IPOs. He holds a BS in Mathematics from UCLA, a paralegal certification from San Francisco State University, and an MBA from UC Berkeley's Haas School of Business.

Joanna Zesiger· Director of Financein

Leah Paquette· Director of Operations and LP Relations· Boston, Massachusetts, United Statesin

Nil Gural· Principal· New Yorkin

Nil Gural is a principal at Polaris Partners, which she joined in 2022, where she works on biotech and healthcare investments. She previously was a manager in Bain & Company's healthcare practice covering pharma and medical devices, and earlier was part of the founding team at Glympse Bio, contributing to its platform technology. She holds a PhD from the Harvard-MIT HST program, where she was an HHMI fellow, and a BS in Biomedical Engineering from Washington University in St. Louis.

Paige Lim· Principal· Singaporein

Paulina Hill· Principal· Cambridge, Massachusetts, United Statesin 𝕏

Paulina Hill combines institutional VC and angel investing—writing $100K–$250K biotech checks to access scientific founders early; a PhD molecular biologist who actively architects complex therapeutics like targeted protein degraders.

Noel Ruane· Venture Partner𝕏

Annie Wihongi· Executive Assistant and Office Manager· Bath, England, United Kingdomin

Daniel Anderson· Scientific Advisory Committee Member

Dave Barrett· Senior Advisory Partner· Boston, Massachusettsin 𝕏

Dave Barrett is a senior advisory partner in Polaris Partners' Boston office who focuses on healthcare technology. He joined Polaris in 2000 after an operating career that included serving as COO of Calico, SVP of worldwide operations at Pure Atria/Rational Software, and various leadership roles over 12 years at Lotus Development. He also serves as a managing partner of Polaris Funds VI-IX and the Polaris Healthcare Technology Opportunities Fund, with particular interest in AI and ML platforms for care management.

db@polarispartners.com

Elizabeth Dowd· Executive Assistant and Office Manager· Boston

Elizabeth Dowd joined Polaris in 2018 as an executive assistant and office manager in the firm's Boston office. Before Polaris, she provided administrative support to various non-profits and worked as a tour guide at historic sites.

Harold Friedman· Chief Financial Officer· San Francisco, California, United Statesin

Harold Friedman serves as Chief Financial Officer at Polaris Partners. He has experience managing financial operations for venture capital and private equity firms with assets ranging from $200 million to $4.5 billion, and works with managing directors, limited partners, and external service providers.

hfriedman@polarispartners.com

JoAnne Trayers· Executive Assistant· Waltham, Massachusetts, United Statesin

JoAnne Trayers joined Polaris Partners in 2001 as executive assistant to co-founder Jon Flint on the technology side of the firm, and more recently moved to the healthcare team supporting Alan Crane. Before Polaris, she supported the CEO and CFO at Allaire Corporation, worked with the senior management team at Powersoft Corporation, and served as operations manager at FirstSense Software.

Kara Greenwood· Executive Assistant· New Yorkin

Kara Greenwood joined Polaris in 2023 as an executive assistant supporting the firm's New York office. She has worked as a c-suite executive assistant across various industries, with prior roles supporting executives at Goldman Sachs, SBE Entertainment, a private family office, and Virtue Labs. She holds a BS in Communications from The University of Tennessee Knoxville.

Kirti Anand· Fund Controller· Singaporein

Kirti Anand joined Polaris in 2022 as fund controller, where she handles fund management and reporting. She previously worked as an Audit Senior Manager at BDO in the asset management group, focusing on alternative investments across venture capital and private equity clients. She is a Certified Public Accountant (Inactive) and holds a Master of Accounting degree from Golden Gate University.

Lauren Crockett· General Counsel and Chief Compliance Officer· San Franciscoin

Lauren Crockett is general counsel and chief compliance officer at Polaris Partners, which she joined in 2019, handling legal, compliance, and operational matters including fundraising, fund management, and deal structuring. She previously served as assistant general counsel at LendingClub Corporation and was a corporate associate at Latham & Watkins, and earlier held legal and government affairs roles at Bain Capital. She holds a JD from Harvard Law School and a BA in history from Dartmouth College.

Liz Wong· Executive Assistant and Office Manager· San Francisco

Liz Wong joined Polaris Partners in 2025 as executive assistant and office manager for the firm's San Francisco office. She previously provided administrative and office management support to finance, advertising, and tech companies including FCB Global, Vantage Point Capital, and Intuit.

Manik Kuchroo· Senior Associate

Maureen St. Pierre· Portfolio Analyst· Boston, Massachusettsin

Maureen St. Pierre joined Polaris Partners in 2002 as a portfolio analyst supporting the finance and investor relations teams. Before Polaris, she worked in auditing, budget and cost accounting, and investment pension financial management at John Hancock Financial Services. She holds a BS in Finance from Siena College and an MBA from Babson College.

Megan Jahan· Accounting Manager· San Francisco

Megan Jahan is the accounting manager at Polaris Partners, which she joined in 2018 in the San Francisco office, working with the finance team on management company accounting. She previously spent over fourteen years in various accounting positions at VantagePoint Capital Partners. She holds a degree in Administrative Office Management from Renton College.

Michelle Pizzi· Senior Operations Associate· Boston

Michelle Pizzi joined Polaris Partners' Boston office in 2019 as a senior operations associate, where she supports the operations team's initiatives. She previously spent five years at The Fulham Group, managing the office and working with the finance department, and earlier held support roles at Mercer. She holds a BA in marketing with a minor in finance from Assumption College.

Molly Wilson· Executive Assistant· Boston, Massachusetts, United Statesin

Molly Wilson joined Polaris in 2002 as executive assistant to co-founder and general partner Terry McGuire. Since 2010, she has co-founded and served as executive administrator for the Global Venture Capital Congress, organizing its annual meetings of venture capital associations worldwide. Her earlier career included executive assistant roles supporting leadership at EMC Corporation, Arch Wireless, Oak Industries, and Brandeis University, and she is a graduate of The Katharine Gibbs School in Boston.

Robert Langer· Scientific Advisory Committee Member

Sean Thornton· Office Coordinator· Bostonin

Sean Thornton joined Polaris Partners' Boston office in 2022 as an office coordinator. Before Polaris, he worked as an assistant office manager at the Above the Rim sports complex.

Alicia Taylor· Fund Controller· United Kingdomin

Alicia Taylor is an Investment Director at Pembroke, where she joined in September 2022, focusing on new investments while supporting existing portfolio companies and their founding teams. She previously worked in Barclays Private Bank's ultra-high net worth investment team and spent three years at a boutique venture capital fund. She holds a first-class BSc in Management from Bristol University, the IMC Certificate, and has passed CFA Level One.

alicia.taylor@pembrokevct.com

Emma Ward· Executive Assistant and Office Manager· London, England, United Kingdomin

Emma Ward is Director of Talent at Pembroke, which she joined in March 2025, where she works with portfolio company leadership teams on Chair, NED, C-suite, and Board hiring. She previously served as European Managing Director of The Talent Business, an executive search firm in the brand and innovation space, and has 25+ years of management experience across brand consultancies and advertising agencies.

Pat Mulach· Vice President· Boston, Massachusettsin 𝕏

Steve Arnold

Founder mafia

The Polaris Partners mafia →

7 people who came through Polaris Partners went on to found or lead other companies.

Amir NashatEntrepreneur PartnerFounded Jnana Therapeutics +3 Robert LangerScientific Advisory Committee MemberFounded Lyndra +2 Alan CraneEntrepreneur PartnerFounded Seismic Therapeutic +1 Pat KinselVenture PartnerFounded Proof +1 Amy SchulmanManaging PartnerFounded Lyndra Brendan HanniganEntrepreneur PartnerFounded Sonrai Security David LucchinoSenior AssociateFounded Frequency Therapeutics

What they invest in

from 104 of 130 portfolio companies

Biotech ×63Healthtech ×44AI & Machine Learning ×30Medical Devices ×26SaaS ×15Deep Tech ×13Digital Health ×13Enterprise Software ×13

HQs:United States×98Belgium×1United Kingdom×1Ireland×1Netherlands×1Singapore×1

Investments · 130 tracked

founders shown can be your intro path

By year:2026 · 5 2025 · 9 2024 · 7 2023 · 4 2022 · 14 2021 · 11 2020 · 12 2019 · 4 2018 · 6 2017 · 9 2016 · 11 2015 · 12118 dated

Adagio TherapeuticsNASDAQ: IVVDNov 2022SEC filingmedium confidence

Invivyd develops monoclonal antibody therapies to prevent and treat serious viral infections, beginning with COVID-19 and expanding to respiratory syncytial virus and measles.

BiotechWaltham, US

Tillman U. Gerngross(Executive Officer, Director)Lynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)Rebecca Dabora(Executive Officer)inEllie Hershberger(Executive Officer)

Board seat Terry McGuireTerrance G. McGuire· per SEC Form D · $23.7M raise · filed Nov 2022

Co-investorsGV (Google Ventures)Fidelity Investments Foresite Capital Mithril Capital Management Omega Funds OrbiMed +3 more

Alectoralector.com in 𝕏NASDAQ: ALECSeries A · Sep 2015

Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.

AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US

Arnon Rosenthal(Ph.D.)inTillman Gerngross(Director)

BoardCarl Gordon(Director)

Board seat Terry McGuire· per SEC Form D

Co-investorsForesite Capital GV (Google Ventures)Mission Bay Capital Mission Biocapital MRL Ventures Fund SV Health Investors

aTYR PHARMAatyrpharma.com in 𝕏NASDAQ: ATYRMar 2015SEC filingmedium confidence

aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.

BiotechHealthtechMedical DevicesSan Diego, US

Paul Schimmel(Founder)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)

BoardAkkaraju Srinivas(Non-Management Director)

Board seat Amir Nashat· per SEC Form D · $76.3M raise · filed Apr 2015

Co-investorsCardinal Partners EcoR1 Capital Sofinnova Ventures Viking Global Domain Associates Domain Partners +2 more

Camp4 Therapeutics CorpNASDAQ: CAMPJun 2022SEC filingmedium confidence

Camp4 Therapeutics develops antisense oligonucleotides targeting regulatory RNAs to increase gene expression and restore healthy protein levels for genetic diseases, with an initial focus on treating SYNGAP1-related developmental and epileptic encephalopathy.

BiotechCambridge, US

Richard Young(Director (Class II))Josh Mandel-Brehm(Chief Executive Officer and Director (Class III))in

BoardMICHAEL HIGGINS(Director)JORGE CONDE(Director)in

Board seat Amir Nashat· per SEC Form D · filed Jun 2022

Co-investors5AM Ventures Andreessen Horowitz Longwood Fund

Cardlyticscardlytics.com in 𝕏NASDAQ: CDLXMay 2017SEC filingmedium confidence

Cardlytics operates a commerce media platform that uses card-linked purchase data to deliver targeted offers and closed-loop measurement for marketers and advertisers, and personalized rewards programs for banks and publishers.

AdTechFintechMarketing TechAtlanta, US

Scott Grimes(Founder)in Lynne Laube(Founder)in Kirk Somers(Executive Officer)in David Evans(Executive Officer)inAmit Gupta(Chief Executive Officer and Director)in

BoardJohn Klinck(Director)in

Board seatBryce Youngren· per SEC Form D · $11.9M raise · filed Jun 2017

Co-investorsBaroda Ventures Canaan Partners Kinetic Ventures, L.L.C.Next Coast Ventures Savano Capital Partners Discovery Capital +2 more

Cartesian Therapeutics (NASDAQ: RNAC)cartesiantherapeutics.com in 𝕏NASDAQ: RNACDec 2016SEC filingmedium confidence

Cartesian Therapeutics is a clinical-stage biotechnology company developing mRNA-based cell therapies aimed at treating autoimmune diseases.

BiotechHealthtechWatertown, US

Metin Kurtoglu(Executive Officer)Omid Farokhzad(Director)Chris Jewell(Executive Officer)in Carsten Brunn(President, CEO & Chairman of the Board)inEmily English(Executive Officer)in Blaine Davis(Executive Officer)in

Board seat Amir Nashat· per SEC Form D · $70M raise · filed Jan 2020

Co-investorsK2 HealthVentures Maryland TEDCO Schooner Capital TEDCO +ND Capital RUSNANO

Cyclerion Therapeuticscyclerion.com in 𝕏NASDAQ: CYCNApr 2019SEC filinghigh confidence

Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device.

BiotechDigital HealthMental HealthCambridge, US

William Huyett(Executive Officer)Mark G. Currie(Executive Officer)inRegina M. Graul(President and Chief Executive Officer)inOle Isacson(Director)Stephanie Lovell(Director)Marsha Fanucci(Director)

Board seat Amy SchulmanTerrance McGuire· per SEC Form D · $24.3M raise · filed Aug 2020

Co-investorsPappas Capital Aberdare Ventures EcoR1 Capital Invus

Dare Biosciencedarebioscience.com in 𝕏NASDAQ: DAREOct 2016SEC filingmedium confidence

Daré Bioscience is a female-led biotech company developing treatments for women's health conditions that are overlooked in the healthcare industry.

BiotechDigital HealthDirect to ConsumerFemTechHealthtechSan Diego, US

MarDee Haring-Layton(Chief Accounting Officer)inSabrina Martucci Johnson(Founder & Chief Executive Officer)Christopher D.T. Guiffre(Executive Officer, Director)Gregg Beloff(Executive Officer)Alejandra V. Carvajal(Executive Officer)Adrian Senderowicz(Executive Officer)

Board seat Alan Crane· per SEC Form D · $1 raise · filed Oct 2016

Co-investorsLilly Ventures Venrock

Fate Therapeuticsfatetherapeutics.comNASDAQ: FATEMay 2015SEC filingmedium confidence

Fate Therapeutics develops investigational cellular immunotherapies to treat autoimmune diseases and cancer.

BiotechDigital HealthHealthtechMedical DevicesSan Diego, US

Christian Weyer(Executive Officer, Director)J. Scott Wolchko(Executive Officer)Daniel Shoemaker(Executive Officer)in Bahram (Bob) Valamehr(President & Chief Executive Officer)in

BoardJohn Mendlein(Director)

Board seat Amir Nashat· per SEC Form D · $10.3M raise · filed Aug 2016

Co-investorsSanofi Ventures Venrock Fidelity Investments OVP Venture Partners

Fractylfractyl.com in 𝕏NASDAQ: GUTSJan 2022SEC filingmedium confidence

Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms.

BiotechHealthtechMedical DevicesLexington, US

Jay Caplan(Founder)in Harith Rajagopalan(Founder)in LISA DAVIDSON(Executive Officer)inDiane Marcou(Executive Officer)in

Board Allan Will(Director)in Nimesh Shah(Director)in

Board seat Amy Schulman· per SEC Form D · $20.1M raise · filed Jan 2022

Co-investorsBessemer Venture Partners Catalio Capital Management, LP Emergent Medical Partners, LLP General Catalyst Mithril Capital Management Domain Associates +1 more

Pulmatrixpulmatrix.comNASDAQ: PULMDec 2018SEC filingmedium confidence

Pulmatrix develops inhaled dry-powder therapies using its proprietary iSPERSE technology, which uses small, dense, dispersible particles to deliver respiratory and non-respiratory drugs via the respiratory system.

BiotechDeep TechHealthtechMedical DevicesFramingham, US

Anand Varadan(Director)inRichard Batycky(Director)Peter Ludlum(Interim Chief Executive Officer)Hojabr Alimi(Executive Officer)Sameer Harish(Executive Officer)

BoardRichard Conley(Director)

Board seatTerrance McGuire· per SEC Form D · $3.7M raise · filed Dec 2018

Co-investors5AM Ventures ALTITUDE LIFE SCIENCE VENTURES ARCH Venture Partners

Scholar Rockscholarrock.com in 𝕏NASDAQ: SRRKSeries A · Dec 2015 · $20M

Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.

BiotechCambridge, US

Nagesh Mahanthappa(Executive Officer, Director)inTimothy Springer(Director)David Hallal(Chief Executive Officer, Chairman and Director)inAkshay Vaishnaw(President of Research & Development and Director)inR. Keith Woods(Chief Operating Officer)inVikas Sinha(Chief Financial Officer)in

Board seat Amir Nashat· per SEC Form D

Co-investorsAisling Capital ARCH Venture Partners EcoR1 Capital The Kraft Group

Scholar Rock Holding Corp, Inc.NASDAQ: SRRKDec 2017SEC filingmedium confidence

Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.

BiotechCambridge, US

Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Akshay Vaishnaw(President of Research & Development and Director)R. Keith Woods(Chief Operating Officer)in

Board seat Amir Nashat· per SEC Form D · $47M raise · filed Jan 2018

Co-investorsSamsara BioCapital ARCH Venture Partners EcoR1 Capital

Seerseer.bio inNASDAQ: SEERDec 2017SEC filingmedium confidence

Seer develops proteomics tools for large-scale protein analysis, including an assay, automation instrument, and analysis software for studying the proteome across human and non-human samples.

BiotechDeep TechHardwareHealthtechBoston, US

Omid Farokhzad(Founder)inPhilip Ma(Executive Officer)Shadi Aryanpour(Executive Officer)David Singer(Director)Omid Cameron Farokhzad(Founder)in

Board seatTerrance McGuire· per SEC Form D · $6M raise · filed Jan 2018

Co-investorsSoftBank Vision Fund Solasta Ventures Wing aMoon Maverick Ventures T. Rowe Price

Vaccinexvaccinex.com in 𝕏OTC: VCNXMay 2017SEC filingmedium confidence

Vaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer.

BiotechHealthtechMedical DevicesRochester, US

Maurice Zauderer, Ph.D.(President and CEO)Maurice Zauderer(Executive Officer, Director)inErnest S. Smith Ph.D.(Executive Officer)Jill Sanchez(Executive Officer)in Ernest S. Smith(Executive Officer)inRaymond Watkins(Executive Officer)in

Board seat Alan Crane· per SEC Form D · $18.2M raise · filed Jul 2017

X4 Pharmax4pharma.com in 𝕏NASDAQ: XFORApr 2016SEC filinghigh confidence

X4 Pharmaceuticals is a biopharmaceutical company developing medicines for people living with rare immune disorders, including chronic neutropenia.

BiotechBoston, US

Mary DiBiase(Executive Officer)inChristophe Arbet-Engels(Executive Officer)inDavid Kirske(Executive Officer)inJohn Volpone(Executive Officer)inMark Baldry(Executive Officer)Adam Craig(Executive Officer, Director)in

Board seat Amy SchulmanTerrance McGuire· per SEC Form D · $50.5M raise · filed May 2017

Co-investorsBain Capital Life Sciences Lumira Ventures New Enterprise Associates (NEA)Partners Resolute Thynk Capital Advent Life Sciences +1 more

Editas Medicineeditasmedicine.com in 𝕏NASDAQ: EDITSeries A · Nov 2013 · $43M

Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.

BiotechDeep TechMedical DevicesCambridge, US

Feng Zhang(Founder)in George Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)in David Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKatrine Bosley(Executive Officer, Director)inVic Myer(Executive Officer)in

Co-investorsEcoR1 Capital GV (Google Ventures)Sofinnova Ventures Viking Global Atlas Venture Deerfield Management Company +2 more

Freenomefreenome.com in 𝕏NASDAQ: FRNMSeries A · Mar 2017 · $65M

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US

Riley Ennis(Founder)inCharles Roberts(Founder)inGabriel Otte(Founder)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)

Co-investorsRA Capital Agent Capital AME Cloud Ventures Andreessen Horowitz Artis Ventures Asset Management Company +15 more

Invivydinvivyd.com in 𝕏NASDAQ: IVVDSeries A · Jul 2020 · $50M

Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications.

BiotechHealthtech

Marc Elia(Founder)in

Co-investorsBain Capital Life Sciences Foresite Capital MRL Ventures Fund Premji Invest RA Capital GV (Google Ventures)+2 more

Leyden Labsleydenlabs.com in✓ verified

Leyden Labs develops nasal sprays containing antibodies that target respiratory viruses such as influenza and COVID at the nasal mucosa to prevent initial infection and transmission.

BiotechDeep TechHealthtechLeiden, NL

Koenraad Wiedhaup(Founder & Chief Executive Officer)in Ronald Brus(Founder & Chief Growth Officer)inJaap Goudsmit(Founding Scientist and Senior Advisor)in Dinko Valerio(Founder and Chair of the Supervisory Board)in Jintanat Ananworanich(Chief Medical Officer)inClarissa Koch(Chief Scientific Officer)in

Co-investorsClavystBio F-Prime Capital GV (Google Ventures)Bluebird Ventures Byers Capital Casdin Capital +7 more

Agbiomeagbiome.comFeb 2022AcquiredSEC filingmedium confidence

US agricultural biotech that discovered microbe-based crop protection products; its assets were sold to Certis Biologicals and Ginkgo Bioworks in 2024.

AgTechResearch Triangle Park, US

Scott Uknes(Manager)inEric Ward(Manager)Paul Schulze-Lefert(President)Michael Koziel(Vice President and Manager)

BoardThomas Dietz(Manager)Kristina Burow(Manager)in

Board seat Amir Nashat· per SEC Form D · $117.2M raise · filed Feb 2022

Co-investorsAliment Capital Blue Horizon Corporation Pontifax AgTech ARCH Venture Partners Bill & Melinda Gates Foundation Leaps by Bayer +1 more

Ankyra Therapeuticsankyratx.com in 𝕏May 2020SEC filingmedium confidence

Ankyra Therapeutics is a biopharmaceutical company developing drugs, with a team that has collectively contributed to bringing seven drugs to global market approval.

BiotechDeep TechHealthtechMedical DevicesAustin, US

Tillman Gerngross(Executive Officer, Director)

Board seatTerrance McGuire· per SEC Form D · $14.5M raise · filed May 2020

Co-investorsGV (Google Ventures)Fidelity Investments Mithril Capital Management Sands Capital Ventures Spring Mountain Capital

Arivalearivale.comMay 2017DefunctSEC filingmedium confidence

Seattle 'scientific wellness' startup that paired genetic, blood and microbiome testing with health coaching; closed in 2019.

HealthtechSeattle, US

Nathan Price(Director)Clayton Lewis(Executive Officer, Director)

BoardTim Kilgallon(Director)

Board seat Terry McGuire· per SEC Form D · $30M raise · filed Jun 2017

Co-investorsCorewell Health Ventures ARCH Venture Partners

Auron Therapeuticsaurontherapeutics.comSeries A · Dec 2025 · $48M

BiotechNewton, US

Katharine Yen(Executive Officer, Director)Kate Yen(Founder)inChristopher Guiffre(Executive Officer)

BoardAlon Lazarus(Director)Anna French(Director)in

Board seat Alexandra Cantley· per SEC Form D

Co-investorsDCVC (Data Collective)Qiming Venture Partners USA Apollo Health Ventures BrightEdge DCVC Bio Qiming Venture Partners

ByHeartbyheart.com inSeries A · May 2026 · $70M

ByHeart is an infant formula company that manufactures science-driven baby formula with its own manufacturing process and supply chain.

ConsumerDirect to ConsumerFoodTechHealthtechNew York, US

Ron Belldegrun(Co-founder)inMia Funt(Founder)in Georg Krause-Vilmar(Executive Officer)in Niall Mullane(Executive Officer)in

Board Hemi Zucker(Director)in

Board seat Amy Schulman· per SEC Form D

Co-investorsEvolution VC Partners OCV Partners AF Ventures Red Sea Ventures Vida Ventures

Cirrus Therapeuticscirrustx.com inAug 2025SEC filingmedium confidence

Cirrus Therapeutics is a biotech developing gene and cell therapies based on ocular immunology to treat dry age-related macular degeneration (AMD), including an AAV gene therapy to restore the IRAK-M immune regulator and a next-generation retinal pigment epithelium (RPE) cell therapy for advanced geographic atrophy.

BiotechHealthtechLongevityCambridge, US

Ying Kai Chan(Co-founder & CEO)inAndrew Dick(Director, Promoter)

BoardKhoo Shih(Director)

Board seat Alexandra Cantley· per SEC Form D · $15.7M raise · filed Aug 2025

Co-investorsClavystBio ZAKA VC

Crossbow Therapeuticscrossbowtx.com inSep 2025SEC filingmedium confidence

Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Alexander Nolte(Executive Officer)in Dmitri Wiederschain(Executive Officer)in

BoardSakae Asanuma(Director)in Briggs Morrison(Executive Officer, Director, Promoter)in Irena Melnikova(Director)in

Board seat Alexandra Cantley· per SEC Form D · $80M raise · filed Sep 2025

Co-investorsLifelink MPM BioImpact Pfizer Venture Investments Biotechnology Value Fund Mirae Asset Venture Investment Pfizer Ventures +1 more

Dewpoint Therapeuticsdewpointx.com in 𝕏Series A · Feb 2022 · $60M

Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.

AI & Machine LearningBiotechDeep TechBoston, US

Richard Young, Ph.D.(Director)inAnthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inIsaac Klein, M.D., Ph.D.(Executive Officer)

Board seat Amir Nashat· per SEC Form D

Co-investorsARCH Venture Partners EcoR1 Capital General Catalyst Samsara BioCapital 6 Dimensions Capital Innovation Endeavors +6 more

Drizlydrizly.comApr 2015SEC filingmedium confidence

On-demand alcohol delivery platform providing consumers with a better way to shop for wine and spirits

Sherborn, US

Justin Robinson(Executive Officer)inNicholas Rellas(Executive Officer, Director)James Cory Rellas(Executive Officer)Joseph Grabmeier(Executive Officer)Jacqueline Flug(Executive Officer)Deborah Poole(Director)

Board seat Pat Kinsel· per SEC Form D · $34.6M raise · filed Dec 2018

Co-investorsAvenir Growth Capital Edmonton Unlimited Reynolds and Company Venture Partners Winklevoss Capital Avenir Suffolk Equity Partners +1 more

Epi Biologicsepibiologics.com inSeries A · Apr 2024 · $73M

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical DevicesSan Mateo, US

Ann Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)

Board Samuel Bjork(Director)in Seiji Miyahara(Director)in

Board seat Alexandra Cantley· per SEC Form D

Co-investorsAvego BioScience Capital GV (Google Ventures)Mission Biocapital Novartis Venture Fund Roche Venture Fund Samsara BioCapital +4 more

Faraday Pharmaceuticalsfaradaypharma.comOct 2022DefunctSEC filingmedium confidence

Seattle biotech that developed FDY-5301 for cardiac and skeletal muscle injury; ceased operations in February 2026.

BiotechSeattle, US

Mark Roth(Executive Officer, Director, Promoter)Brian Blackman(Executive Officer)Simon Tulloch(Executive Officer)Stephen Hill(Executive Officer, Director)

Board Paulina Hill(Director)in Steven Gillis(Executive Officer, Director, Promoter)in

Board seatTerrance McGuire· per SEC Form D · $102.8M raise · filed Nov 2022

Co-investorsARCH Venture Partners OUP (Osage University Partners)

Glympse Bioglympsebio.comDec 2021AcquiredSEC filingmedium confidence

Cambridge, MA biotechnology company developing injectable synthetic biomarkers for noninvasive disease staging and treatment monitoring.

BiotechCambridge, US

Gabriel Kwong(Executive Officer)in Sangeeta Bhatia in Roopom Banerjee(Executive Officer)in

Board Theresia Gouw(Director)in Stan Lapidus(Director)in

Board seat Amy Schulman· per SEC Form D · $18M raise · filed Dec 2021

Co-investorsGreatPoint Ventures Acrew Capital ARCH Venture Partners Aspect Ventures Catalio Capital Management CRV (Charles River Ventures)+7 more

Iora Health 𝕏Series B · Jan 2015 · $14Macquired by One Medical

Iora Health was a primary care company focused on value-based care for Medicare-eligible seniors, operating clinics with a team-based model including health coaches.

Digital HealthHealthtechWellness & FitnessSan Francisco, US

RUSHIKA FERNANDOPULLE(Executive Officer, Director)inCHRISTOPHER J. MCKOWN(Executive Officer, Director)DAVID FIELDING(Executive Officer)ALEXANDER PACKARD(Executive Officer)inDAVID JUDGE(Executive Officer)

Board STEPHEN KNIGHT(Director)in

Board seat Terry McGuire· per SEC Form D

Co-investors.406 Ventures Dag Ventures F-Prime Capital Flare Capital Partners GV (Google Ventures)Lifeforce Capital +10 more

Ironwood Pharmaceuticalsironwoodpharma.com in 𝕏Sep 2016SEC filingmedium confidence

Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing treatments for GI diseases.

BiotechDigital HealthHealthtechCambridge, US

PETER M. HECHT(Executive Officer, Director)in MARK G. CURRIE(Executive Officer)inHALLEY E. GIBLERT(Executive Officer)THOMAS GRANEY(Executive Officer)THOMAS A. MCCOURT(Executive Officer)in

Board seatTerrance G. Mcguire· per SEC Form D · $150M raise · filed Oct 2016

Co-investorsF-Prime Capital Mountain Group Capital Ridgeback Capital Venrock Maverick Ventures

Jnana Therapeuticsjnanatx.com in 𝕏Series A · Dec 2017 · $50Macquired by Otsuka

Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins.

AI & Machine LearningBiotechDeep TechAustin, US

Joel Barrish(Chief Scientific Officer)Donald W. Nicholson(Director)Matthew Hammond(Director)Caroline Stark Beer(Chief Business Officer)Carlo Rizzuto(Director)Annie C. Chen(Director)

Board seatTerrance G. McGuire· per SEC Form D

Co-investorsAvalon BioVentures Bain Capital Life Sciences Pfizer Venture Investments RA Capital Pfizer Ventures Versant Ventures

Kallyopekallyope.com inSep 2015SEC filingmedium confidence

Kallyope is a biotechnology company founded by neuroscientists that discovers and develops novel therapeutics targeting neural networks, with a lead candidate in pivotal studies for acute migraine treatment and metabolism programs approaching clinical studies.

BiotechHealthtechNew York City, US

Tom Maniatis(Founder)Nancy Thornberry(Executive Officer, Director)inKenneth Clark(Executive Officer)Charles Zuker(Founder)Richard Axel(Founder)

Board seat Terry McGuire· per SEC Form D · $44M raise · filed Oct 2016

Co-investorsDns Capital Illumina Ventures Lux Capital The Column Group Two Sigma Ventures

KSQ Therapeuticsksqtx.com in 𝕏Sep 2018

KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)inFRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)Qasim Rizvi(Chief Executive Officer)inJAMES GILBERT(Director)

Board seat Alan Crane· per SEC Form D

Co-investorsAlpha Wave Global ARCH Venture Partners Flagship Pioneering LAV LG Technology Ventures Lilly Asia Ventures +3 more

Metacrinemetacrine.comJan 2015SEC filingmedium confidence

San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.

BiotechSan Diego, US

Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)

Board Kristina Burow(Director)in Richard Heyman(Director)in

Board seat Amir Nashat· per SEC Form D · $37.8M raise · filed Nov 2016

Co-investorsage1 EcoR1 Capital LAV LifeSci Venture Partners Lilly Asia Ventures New Enterprise Associates (NEA)+8 more

Navitor Pharmaceuticalsnavitorpharma.com inSeries A · Dec 2015 · $24M

BiotechCambridge, US

Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)in

Board Jean-Francois Formela(Director)in Marian Nakada(Director)in Brian Gallagher(Director)in

Board seat Alan Crane· per SEC Form D

Co-investorsage1 Brace Pharma Sanofi Ventures Atlas Venture SR One Capital Management

Noetiknoetik.ai in 𝕏Series A · Aug 2024 · $40M

Noetik builds AI models to identify cancer patients most likely to respond to treatments and to discover new oncology drug targets.

AI & Machine LearningBiotechHealthtechSouth San Francisco, US

Jacob Rinaldi(Founder)inRonald Alfa(Executive Officer, Director, Promoter)Ron Alfa, MD, PhD(Co-Founder, CEO)inRon Alfa(Founder)Ron Alfa Jacob Rinaldi(Founder)

Board James Hardiman(Director)in

Board seat Amy Schulman· per SEC Form D

Co-investors11.2 Capital Breakout Labs Breakout Ventures Catalio Capital Management, LP EPIC VENTURES Intermountain Health +6 more

Nomad Healthnomadhealth.com inSeries B · Dec 2025 · $12M

Nomad Health operates an online marketplace that matches travel nurses and allied health clinicians with temporary healthcare jobs based on their profiles and preferences.

Digital HealthHealthtechMarketplacesNew York, US

Maxwell Laurans(Director)Alexi Nazem(Co-Founder & Board Member)in Justin Lambert(CEO)inWilliam Eager(Vice President of Engineering)Alexander Pease(Vice President of Product)Justine Lelchuk(COO)in

Board seat Brian Chee· per SEC Form D

Co-investorsAlleyCorp First Round Capital Icon Ventures RRE Ventures .406 Ventures Adams Street Partners +1 more

Pandion Therapeuticspandiontx.comSeries A · Jan 2018 · $58Macquired by Merck · Feb 2021 · $1.9B

Developing biologic therapies for autoimmune disorders; acquired by Merck for $1.85B in 2021.

BiotechCambridge, US

Jo Viney(Executive Officer)Rahul Kakkar(Executive Officer, Director)in Anthony Coyle(Executive Officer, Director)inChristopher Fuglesang(Director)Donald Frail(Director)Daniel Becker(Director)

Board seat Alan Crane· per SEC Form D

Co-investorsAccess Biotechnology JDRF T1D Fund Mission Biocapital RA Capital SR One Capital Management Versant Ventures

Podimetricspodimetrics.com inApr 2022SEC filingmedium confidence

Podimetrics offers a remote monitoring and care program for people with complex diabetes, centered on the SmartMat device that collects foot-health data to enable early intervention and prevent complications such as amputations.

Digital HealthHealthtechMedical DevicesSomerville, US

David Linders(Executive Officer, Director)inJonathan Bloom(Executive Officer, Director)

Board Aaron Sandoski(Director)in

Board seat Alexandra Cantley· per SEC Form D · $60M raise · filed Apr 2022

Co-investorsNorwich Ventures Scientific Health Development SV Health Investors Rock Health

Primmune Therapeuticsprimmunerx.com in 𝕏Series A · Nov 2020 · $27M

Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy.

BiotechHealthtechCarlsbad, US

James Appleman(SVP, R&D and CSO, Cofounder)Paulo Rangel(Chief Business Officer and Cofounder)inStephen Webber(Vice President, Medicinal Chemistry, and Cofounder)inCharles McDermott(President & CEO, Director)

BoardTodd J Harris(Director)in

Board seat Amir Nashat· per SEC Form D

Co-investorsBioBrit BioRock Ventures Samsara BioCapital Bioqube Ventures Oberland Capital

Quralisquralis.com in 𝕏Sep 2025SEC filingmedium confidence

QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.

BiotechDeep TechMedical DevicesCambridge, US

Kevin Eggan(Founder, QurAlis; Group Vice President, Head of Research and Early Development, BioMarin Pharmaceutical)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Founder, Chief Executive Officer)in Shafique Virani(Executive Officer)in Jason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in

Board seat Amy Schulman· per SEC Form D · $24.9M raise · filed Sep 2025

Co-investorsALS Investment Fund Dolby Family Ventures Droia Ventures Inkef MC Healthcare Ventures Mission Biocapital +8 more

Seismic Therapeuticseismictx.com in 𝕏Series A · Sep 2024 · $100M

Seismic Therapeutic is a clinical-stage biotechnology company that uses machine learning to discover and develop immunology therapies for autoimmune diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesBoston, US

Timothy A. Springer(Scientific Advisor / Founder)Jo Viney, PhD(Founder, President and Chief Executive Officer)Alan Crane(Founder and Chairman of Seismic Therapeutic; Polaris Partners)inTim Springer, PhD(Founder of Seismic Therapeutic; Harvard Medical School and Boston Children's Hospital)Debora Marks, PhD(Founder)Andrew Kruse, PhD(Founder)

Board seat Alan Crane· per SEC Form D

Co-investorsBessemer Venture Partners GV (Google Ventures)Lightspeed Venture Partners Mana Ventures

Sofregensofregen.com inSep 2016SEC filingmedium confidence

Sofregen develops silk protein-based biomaterials and medical devices for soft tissue regeneration in aesthetic and surgical procedures.

BiotechHealthtechMedical DevicesNew MaterialsCambridge, US

Milan Kofol(Executive Officer)Doug Sheldon(Director)Anh Hoang(Executive Officer)Howard Weisman(Executive Officer, Director)

Board seat Amir Nashat· per SEC Form D · $9.7M raise · filed Sep 2017

Co-investorsAnzu Partners

SunBird Biosunbirdbio.comOct 2024 · $14M

Biotechnology company developing blood-based diagnostic tests for neurological disorders and early-stage cancer.

Cambridge, US

Board seat Alexandra Cantley· per SEC Form D

Co-investorsAlumni Ventures ARCH Venture Partners ClavystBio S32

Syros Pharmaceuticals, Inc.syros.comDec 2020SEC filingmedium confidence

Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.

BiotechCambridge, US

Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)

Board seat Amir Nashat· per SEC Form D · $121.6M raise · filed Dec 2020

Co-investorsAisling Capital ARCH Venture Partners Quan Capital Alexandria Ally Bridge Group Bain Capital +11 more

Tectonic Therapeutictectonictx.com inSeries A · Apr 2021 · $80M

Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.

AI & Machine LearningBiotechMedical DevicesWatertown, US

Timothy A. Springer(Co-Founder)Andrew C. Kruse(Director)Alise Reicin(Executive Officer, Director)inDaniel Lochner(Executive Officer)Marc Schwabish(Executive Officer)inPeter McNamara(Executive Officer)in

Board seat Terry McGuire· per SEC Form D

Co-investorsEcoR1 Capital Vida Ventures Ally Bridge Group Clarus Ventures Soleus Capital

Allstacksallstacks.com in 𝕏

Allstacks is an AI-agent platform that connects data from software development tools (Jira, GitHub, GitLab, Jenkins) to provide engineering teams and leaders with delivery metrics, risk alerts, and recommendations for planning, managing, and optimizing software creation.

AI & Machine LearningDeveloper ToolsEnterprise SoftwareRaleigh, US

Jeremy Freeman(Founder)in Hersh Tapadia(Founder)inDarrell J. Freeman, Jr.(Executive Officer, Director)Scot Sherwood(Director)

Board Andrew Drylie(Director)in Firas Raouf(Director)in

Co-investorsAtlassian Ventures Companyon Ventures CreativeCo First Rays Venture Partners Gutbrain Ventures Hyperplane Venture Capital +9 more

Armorbloxarmorblox.com 𝕏Series B · Feb 2021 · $30Macquired by Cisco

Armorblox provides email security services, including customer support for handling security issues for its business customers.

CybersecurityEnterprise SoftwareSaaS

Anand Raghavan(Founder)Arjun Sambamoorthy(Founder)Chetan Anand(Founder)Dhananjay Sampath(Founder)

Co-investorsMango Capital Next47 Point72 Ventures S Ventures Tau Ventures A.Capital Ventures +3 more

August Bioservicesaugustbio.com inSeries A · May 2021 · $24M

August Bioservices is a contract research, development, and manufacturing organization (CDMO) specializing in sterile injectables, offering end-to-end services from development to commercial manufacturing.

Advanced ManufacturingBiotechHealthtechMedical DevicesNew Brunswick, US

Co-investorsOak HC/FT

Avitideavitide.comSeries C · Aug 2015 · $8Macquired by Repligen

Repligen provides bioprocessing technologies—including process intensification, tangential flow filtration, chromatography, process analytics, and single-use fluid management—for upstream and downstream biopharmaceutical workflows.

BiotechHardwareMedical DevicesLebanon, US

Tillman Gerngross(Director)Errik Anderson(Director)inWarren Kett(Executive Officer)Jon Sheller(Executive Officer)Kevin Issett(Executive Officer, Director)Kevin Isett(Executive Officer, Director)

Co-investorsOrbiMed SV Health Investors Borealis Ventures Mithril Capital Management Neomed Management Sands Capital Ventures +1 more

B12b12.io in 𝕏Series A · Jul 2016 · $12M

B12 offers an AI-powered website builder that generates a complete first draft of a website, online store, portfolio, blog, or web app from a text prompt, which users can then refine via an AI agent or visual editor.

AI & Machine LearningMarketing TechSaaS

Nitesh Banta(Founder)inAdam Marcus(Founder)in

Co-investorsFrancisco Partners Lightbank Lux Capital Suffolk Equity Partners Brand Capital International Founder Collective +6 more

Baxter Planningbaxterplanning.com inMay 2024

Baxter Planning provides software and services for service supply chain management, serving enterprises managing complex operational logistics and supplier networks.

AI & Machine LearningEnterprise SoftwareLogistics & Supply ChainSaaS

Anton Chilton(Chief Executive Officer)in

Co-investorsGolub Growth Marlin Equity Partners

Cohere Healthcoherehealth.com inSeries B · Apr 2021 · $36M

Cohere Health provides a platform aimed at aligning the interests of patients, physicians, and health plans to support care decisions and improve member outcomes.

AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechSaaSBoston, US

Siva Namasivayam(Executive Officer, Director)inRobert Shepardson(Executive Officer)in Kristen Carucci(Executive Officer)inDuncan Reese(Executive Officer)

BoardDavid Barrett(Director)Amir Debourou(Director)

Co-investorsCota Capital Flare Capital Partners Longitude Capital Deerfield Management Company Define Ventures Temasek

Dyno Therapeuticsdynotx.com in 𝕏Seed · May 2020 · $9M

Dyno Therapeutics develops artificial intelligence-powered genetic technologies for gene therapy, specifically engineering adeno-associated virus (AAV) capsids to improve gene delivery for treating genetic diseases.

AI & Machine LearningBiotechWatertown, US

Eric Kelsic(Founder)in Sam Sinai(Founder)in Adrian Veres(Founder)in George Church(Scientific Cofounder, SAB)in Tomas Bjorklund(Scientific Co-founder, SAB)in Alan Crane(Founder)in

Co-investorsAndreessen Horowitz CRV (Charles River Ventures)GENERAL INCEPTION GV (Google Ventures)Lux Capital Obvious Ventures +2 more

Egnyteegnyte.com in 𝕏

Egnyte provides software for protecting and managing business-critical content across organizations of all sizes.

AI & Machine LearningCloud ComputingCybersecurityEnterprise Software

Vineet Jain(Chief Executive Officer)in Amrit Jassal(Founder)in

Co-investorsTA Associates GI Partners Floodgate Golub Growth GV (Google Ventures)Menlo Ventures +3 more

Engine Bioenginebio.comSeries A · May 2021 · $43M

Engine Bio presents itself as a company working on new cancer medicines.

BiotechSingapore, SG

Daphne Teo(Founder)in

Co-investorsClavystBio NSG Ventures WI Harper Group

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

1366 Technologies 480 Biomedical Amagma, Inc.Athletes' PerformanceBe Me Health Blue Rabbit Ventures Cardurion Pharmaceuticals, Inc.Freenome Holdings Icelandic Provisions Lyndra Microchips Biotech Morphic Holding, Inc.Pulmatrix Operating Sequelae Seventh Sense Biosystems TRex Holdings Inc.XTuit PharmaceuticalsAnkyraApnex MedicalArsanisBlackThorn TherapeuticsFirst OpinionJibJab Bros StudiosKnowledge FactorLarkspur BiosciencesLiving ProofSea PharmaceuticalsTessa TherapeuticsTome BiosciencesTropicU S HealthVestYourBio Health

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 35

21 IPOs · 14 acquisitions · showing 27

Adagio TherapeuticsNASDAQ: IVVDAlectorNASDAQ: ALECaTYR PHARMANASDAQ: ATYRCamp4 Therapeutics CorpNASDAQ: CAMPCardlyticsNASDAQ: CDLXCartesian Therapeutics (NASDAQ: RNAC)NASDAQ: RNACCyclerion TherapeuticsNASDAQ: CYCNDare BioscienceNASDAQ: DAREFate TherapeuticsNASDAQ: FATEFractylNASDAQ: GUTSPulmatrixNASDAQ: PULMScholar RockNASDAQ: SRRKScholar Rock Holding Corp, Inc.NASDAQ: SRRKSeerNASDAQ: SEERVaccinexOTC: VCNXX4 PharmaNASDAQ: XFOREditas MedicineNASDAQ: EDITFreenomeNASDAQ: FRNMInvivydNASDAQ: IVVDIora Healthacq. by One MedicalJnana Therapeuticsacq. by OtsukaPandion Therapeuticsacq. by MerckArmorbloxacq. by CiscoAvitideacq. by RepligenJibeacq. by iCIMSLocalyticsacq. by UplandLogEntriesacq. by Rapid7

Portfolio news

latest coverage across their companies

Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY | Invivyd

Invivyd · investors.invivyd.com · Sep 1, 2026

Recurly and Justt target the rising cost of chargebacks

Recurly · fintech.global · Aug 21, 2026

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis - BioSpace

Fate Therapeutics · biospace.com · Aug 14, 2026

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Ironwood Pharmaceuticals · finance.yahoo.com · Aug 6, 2026

Gates Foundation backs Leyden Labs' €40M raise: Can a nasal spray do what 80 years of flu vaccines couldn't — TFN

Leyden Labs · techfundingnews.com · Jun 25, 2026

Pulmatrix Announces First Quarter 2026 Financial Results

Pulmatrix · prnewswire.com · May 15, 2026

Primmune Therapeutics Announces Additional Close of Series B Financing

Primmune Therapeutics · globenewswire.com · Jan 26, 2026

Preply Raises $150 Million to Shape the Future of Education through Human-Led, AI-Enhanced Learning

Preply · prnewswire.com · Jan 21, 2026

Fund performance · per public LP disclosures · 3

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Polaris Growth FundLPs: Los Angeles City Employees' Retirement System, Pension Reserves Investment Management Board	2018	—	36.8%	2.86x	0.57x
Polaris Partners VIIILPs: Hawaii Employees' Retirement System, Los Angeles City Employees' Retirement System	2017	—	15.8%	2.08x	1.10x
Polaris Partners VIILPs: Los Angeles City Employees' Retirement System, Hawaii Employees' Retirement System	2014	—	8.5%	1.88x	0.68x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

How many investments has Polaris Partners made?: Polaris Partners has 130 tracked investments, 35 of which have exited, including 16 dated in the last 24 months.
What stage does Polaris Partners invest at?: Polaris Partners invests at the Seed, Series A, Series B, Series C, Growth stages.
What is Polaris Partners's typical check size?: Polaris Partners typically writes checks of $500K – $5M.
What sectors does Polaris Partners focus on?: Polaris Partners focuses on Biotech, Consumer, Digital Health, Healthtech.
Where is Polaris Partners located?: Polaris Partners is headquartered in Boston, US.

Media · Podcasts & interviews

featuring the team

Tech Investing Mastermind: Terry McGuire- Co-founder of Polaris Partners & Chairman Emeritus of NVCA

Grace Gong · Terry McGuire

Fireside Chat with Robert Langer (KI) and Terry McGuire (Polaris Partners)

KochInstituteMIT · Terry McGuire

Co-investors · 135

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.

Both backed · 15

Pulmatrix Scholar Rock Scholar Rock Holding Corp, Inc.Agbiome Arivale Dewpoint Therapeutics Faraday Pharmaceuticals Glympse Bio KSQ Therapeutics Matter Neuroscience Metacrine SunBird Bio Syros Pharmaceuticals, Inc.VolastraTome Biosciences

$50K – $250M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 14

Adagio Therapeutics Alector Editas Medicine Freenome Invivyd Ankyra Therapeutics Dyno Therapeutics Egnyte Epi Biologics Freenome Holdings Iora Health Leyden Labs Seismic TherapeuticBlackThorn Therapeutics

$250K – $50M

Andreessen Horowitz

Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.

Both backed · 7

Camp4 Therapeutics Corp Freenome Dyno Therapeutics FidoCure Freenome Holdings LobTome Biosciences

$500K – $50M

RA Capital

RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.

Both backed · 7

Adagio Therapeutics Freenome Invivyd Freenome Holdings Jnana Therapeutics Pandion Therapeutics T2 Biosystems

General Catalyst

General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.

Both backed · 6

Fractyl Armorblox B12 Dewpoint Therapeutics Lob OM1

$30M

Bessemer Venture Partners

Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.

Both backed · 6

Fractyl Folx Fridge Seismic Therapeutic SimplyInsured Soufflé Therapeutics

$50K – $100M

F-Prime Capital

F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.

Both backed · 6

Iora Health Ironwood Pharmaceuticals Leyden Labs Recurly U S HealthVestSimon AI

$3M – $10M

SV Health Investors

SV Health Investors is a global private equity and venture capital platform dedicated to healthcare, running specialized funds across biotechnology (including dementia), healthcare growth equity, and medtech.

Both backed · 6

Alector Avitide Podimetrics QuralisArsanisTRexBio

$1M – $20M

.406 Ventures

.406 Ventures is an early-stage venture capital firm that partners with founders building companies in healthcare, data and AI, and cybersecurity.

Both backed · 5

Iora Health Nomad Health Simon Data TausightSimon AI

$1M – $4M

Mithril Capital Management

Mithril Capital Management is a multi-billion-dollar investment firm launched in 2012 with a 'Building to Last' mission, backing technology teams building durable businesses in industries overdue for change. Its committed funds are anchored by investor Peter Thiel.

Both backed · 5

Adagio Therapeutics Fractyl Invivyd Ankyra Therapeutics Avitide

Mission Biocapital

Mission BioCapital provides early-stage capital and shared lab space to life science entrepreneurs, supporting companies from idea through clinic and exit.

Both backed · 5

Alector Epi Biologics Pandion Therapeutics QuralisZag Bio

$500K

Atlas Venture

Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.

Both backed · 4

Editas Medicine Amagma, Inc.Morphic Holding, Inc.Navitor Pharmaceuticals

$500K – $1M

▶123 more co-investors

5AM Ventures Sanofi Ventures Flagship Pioneering Pfizer Venture Investments Vida Ventures Catalio Capital Management, LP Lightspeed Venture Partners Techstars DCVC (Data Collective)CRV (Charles River Ventures)Sapphire Ventures Floodgate Venrock OrbiMed Flare Capital Partners S32 Aisling Capital Borealis Ventures Insight Partners Menlo Ventures RRE Ventures SoftBank Vision Fund Locus Ventures EQT Life Sciences Versant Ventures SR One Capital Management Johnson & Johnson Innovation – JJDC MPM BioImpact Domain Associates Vivo Capital Define Ventures Qiming Venture Partners aMoon HealthQuest Capital Khosla Ventures Founder Collective Uncork Capital Foundation Capital B Capital Group Norwest Venture Partners Canaan Partners Oak HC/FT Freestyle Capital Headline Scale Venture Partners Obvious Ventures Meritech Capital Partners Next47 Maveron Lowercase Capital US Venture Partners Unusual Ventures Left Lane Capital Zetta Venture Partners Wildcat Venture Partners Javelin Venture Partners Owl Ventures Hoxton Ventures Scrum Ventures Amasia Highbury Holdings Artis Ventures Ten Eleven GreatPoint Ventures Autotech Ventures Market One Capital Digitalis Ventures Kurma Partners Advent Life Sciences RiverVest Venture Partners Apollo Health Ventures +ND Capital Vertex Ventures HC Broadview Ventures Greylock Partners Benchmark Felicis Ventures FJ Labs Coatue Management Eniac Ventures Goat Capital NextView Ventures Bling Capital C2 Investments Stellar Capital Resolute Ventures Stride VC Bonfire Ventures 01 Advisors Harrison Metal BAM Ventures Accomplice Village Global 75 & Sunny Better Tomorrow Ventures Standard Capital NextGen Venture Partners Saga Ventures 23andMe Moxxie Ventures Breakthrough Energy Ventures Highland Capital Partners foobar.vc VitalStage Ventures BIOSPRING PARTNERS Samsung Next Strata Capital Partners Forbion Pillar VC Ascension Ventures Asset Management Ventures Abingworth byFounders Republic Capital (ex Republic Labs)Vinyl Capital Alta Partners Cofounders Capital Medical Excellence Capital Pontifax Venture Capital Avoro Capital Advisors ACORN BIOVENTURES Altitude Ventures Management, Llc 3TS Capital Partners

Firms observed investing alongside Polaris Partners, from public investor directories. Shared companies are the overlap with Polaris Partners's recorded portfolio.

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Bessemer Venture Partners

Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.

$50K – $100M

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

Felicis Ventures

Felicis is a venture capital firm that backs early-stage founders, investing primarily at Seed and Series A across artificial intelligence, cybersecurity and defense, global resilience and energy, and health and bio.

$500K – $15M